Peritoneal dialysis patients are at an increased risk of Gram-positive organism infections because of disrupted skin barrier function, presence of a peritoneal catheter, and a deficient immunological system. In particular, the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections is clinically challenging. Herein, we present a case of MRSA peritonitis that showed no response to a 14-day treatment with intraperitoneal vancomycin. To overcome unresponsiveness to vancomycin, we shifted the regimen to intraperitoneal daptomycin (given every 6 h through manual peritoneal dialysate exchanges) and oral rifampin (300 mg twice daily). The peritonitis resolved without sequelae or relapse. We suggest daptomycin and rifampin as an alternative combination therapy for MRSA infections that may otherwise remain unresolved.

Keywords:
Daptomycin, Methicillin-resistant Staphylococcus aureus peritonitis, Peritoneal dialysis, Rifampin, Vancomycin
1.
Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, Briggs JP, Sexton DJ, Kaye KS: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592–598.
2.
Deresinski S: Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005;40:562–573.
3.
Li PKT, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye WC, Salzer W, Schaefer F, Struijk DG: Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010;30:393–423.
4.
Kowalski TJ, Berbari EF, Osmon DR: Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin Proc 2005;80:1201–1207.
5.
Ponticelli C: New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients. Nephro Dial Transplant 2007;1:27–32.
6.
CDC: Vancomycin-resistant Staphylococcus aureus – New York. MMWR 2004;15:322–323.
7.
Cui L, Iwamoto A, Lian JQ, Neoh HM, Maruyama T, Horikawa Y, Hiramatsu K: Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;2:428–438.
8.
Blunden M, Zeitlin D, Ashman N, Fan SLS: Single UK centre experience on the treatment of PD peritonitis-antibiotic levels and outcomes. Nephrol Dial Transplant 2007;22:1714–1719.
9.
French GL: Bactericidal agents in the treatment of MRSA infections – the potential role of daptomycin. J Antimicrob Chemother 2006;6:1107–1117.
10.
Stein GE, Craig WA: Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518–524.
11.
Wilcox MH: Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 2005;13:2315–2326.
12.
Baltz RH, Miao V, Wrigley SK: Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep 2005;22:717–741.
13.
Sauermann R, Rothenburger M, Graninger W, Joukhadar C: Daptomycin: a review 4 years after first approval. Pharmacolog 2008;81:79–91.
14.
Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC: Increased killing of Staphylococci and Streptococci by daptomycin compared with cefazolin and vancomycin in an In vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003;12:3764–3767.
15.
Bahte SK, Bertram A, Burkhardt O, Martens-Lobenhoffer J, Goedecke V, Bode-Böger SM, Hiss M, Kielstein MJT: Therapeutic serum concentrations of daptomycin after intraperitoneal administration in a patient with peritoneal dialysis-associated peritonitis. J Antimicrob Chemother 2010;10:1312–1313.
16.
Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK: Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant Enterococcus peritonitis. Am J Kidney Dis 2009;54:538–541.
17.
Hassoun AA, Coomer RW, Mendez-Vigo L: Intraperitoneal daptomycin used to successfully treat vancomycin-resistant Enterococcus peritonitis. Perit Dial Int 2009;29:671–673.
18.
Dasgupt MK, Larabie M: Biofilms in peritoneal dialysis. Perit Dial Int 2001;21:26–29.
19.
Stewart PS, Costerton JW: Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135–138.
20.
Stewart PS, Davison WM, Steenbergen JN: Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 2009;8:3505–3507.
21.
LaPlante KL, Mermel LA: In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007;8:2239–2246.
22.
Edmiston JCE, Goheen MP, Seabrook GR, Johnson CP, Lewis BD, Brown KR, Towne JB: Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006;3:344–354.
23.
Rao N, Regalla DM: Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res 2006;451:34–37.
24.
Credito K, Lin G, Appelbaum PC: Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 2007;4:1504–1507.
25.
Rand KH, Houck H: Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004;3:530–532.
26.
Rand KH, Houck HJ: Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004;8:2871–2875.
27.
Schmitz FJ, Fluit AC, Hafner D, Beeck A, Perdikouli M, Boos M, Scheuring S, Verhoef J, Kohrer K, Von Eiff C: Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2000;11:3229–3231.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.